source
- FDA’s radical transparency policy for rejections runs into legal uncertaintyHaving started to publish CRLs without consulting the public, the FDA is under pressure to change course amid concerns it failed to openly and fully evaluate a complex issue.BioSpace · 10d ago↗ source
- 2026 IPO class blooms again as BlossomHill, Latigo set sights on NasdaqEighteen companies have gone public this year so far, putting 2026 on pace to record the highest number of IPOs since the pandemic-driven high of 2021.BioSpace · 10d ago↗ source
- Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvalsThe FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for…